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Abstract 
Recombinant monoclonal antibodies (mAbs) are one of today’s most successful therapeutic classes in inflammatory 
diseases and oncology. A wider accessibility and implementation, however, is hampered by the high product cost and 
prolonged need for frequent administration. The surge in more effective mAb combination therapies further adds 
to the costs and risk of toxicity. To address these issues, antibody gene transfer seeks to administer to patients the 
mAb-encoding nucleotide sequence, rather than the mAb protein. This allows the body to produce its own medicine 
in a cost- and labor-effective manner, for a prolonged period of time. Expressed mAbs can be secreted systemically or 
locally, depending on the production site. The current review outlines the state of play and clinical prospects of anti-
body gene transfer, thereby highlighting recent innovations, opportunities and remaining hurdles. Different expres-
sion platforms and a multitude of administration sites have been pursued. Viral vector-mediated mAb expression 
thereby made the most significant strides. Therapeutic proof of concept has been demonstrated in mice and non-
human primates, and intramuscular vectored mAb therapy is under clinical evaluation. However, viral vectors face 
limitations, particularly in terms of immunogenicity. In recent years, naked DNA has gained ground as an alternative. 
Attained serum mAb titers in mice, however, remain far below those obtained with viral vectors, and robust pharma-
cokinetic data in larger animals is limited. The broad translatability of DNA-based antibody therapy remains uncer-
tain, despite ongoing evaluation in patients. RNA presents another emerging platform for antibody gene transfer. 
Early reports in mice show that mRNA may be able to rival with viral vectors in terms of generated serum mAb titers, 
although expression appears more short-lived. Overall, substantial progress has been made in the clinical translation 
of antibody gene transfer. While challenges persist, clinical prospects are amplified by ongoing innovations and the 
versatility of antibody gene transfer. Clinical introduction can be expedited by selecting the platform approach cur-
rently best suited for the mAb or disease of interest. Innovations in expression platform, administration and antibody 
technology are expected to further improve overall safety and efficacy, and unlock the vast clinical potential of anti-
body gene transfer.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Purpose of the review
This review provides an elaborate overview of the state 
of play and clinical prospects of in  vivo antibody gene 
transfer. Focus includes hallmarks of the applied expres-
sion platforms, key pre-clinical and clinical studies, 
recent innovations, opportunities and remaining clinical 
hurdles.
Recombinant therapeutic antibodies
Therapeutic market and impact
In 1986, the clinical approval of the first monoclonal anti-
body (mAb), Orthoclone OKT3, initiated a new era in 
biological therapeutics. Since then, mAb products have 
grown to become the dominant class within the biophar-
maceutical market [1, 2]. mAbs today are approved for 
the treatment of cancer and autoimmune, inflammatory 
and infectious diseases [3–5]. Applications thereby range 
from a few thousand patients or less for orphan indica-
tions to millions of patients for diseases such as asthma 
and rheumatoid arthritis [1]. A variety of mAb prod-
ucts have been established, ranging from conventional 
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full-length immunoglobulins, mostly isotype G (IgG), 
to fusion proteins and minimal fragments. As of May 
2017, 63 mAb products have been approved in the US 
or Europe for therapeutic use [6]. In 2013, 18 mAb prod-
ucts achieved annual sales of over $1 billion, with six of 
them (adalimumab, infliximab, etanercept, rituximab, 
bevacizumab and trastuzumab) having sales of more than 
$6 billion [1]. In addition, immune checkpoint inhib-
iting mAbs have recently reignited the field of cancer 
immunotherapy. This market segment alone is expected 
to increase from approximately $1 billion in 2013 to in 
excess of $7 billion in 2020 [7]. At the current approval 
rate of approximately four new products per year, about 
70 mAb products will be on the market by 2020, with a 
projected combined world-wide sales of nearly $125 
billion [1]. As the biopharmaceutical industry further 
evolves, the number and types of diseases that can ben-
efit from mAb products will continue to increase [2].
Current issues
Production cost and product pricing
Price tags of $100,000 or more per mAb treatment course 
are no longer an exception [8, 9]. The large size and complex 
nature of mAb biologics require a costly production and 
purification process, and extensive downstream quality con-
trol. Manufacturing of mAbs is therefore far more expensive 
than e.g. small molecules or antibiotics. This clearly impacts 
the cost, but it is not the main contributor to the final prod-
uct price. With economies of scale into play, production 
costs are around $50–100 per gram of mAb [10]. In con-
trast, US wholesale prices in the first quarter of 2015, e.g. in 
the field of immune checkpoint inhibitors, ranged between 
$29,000 and $157,000 per gram of mAb [8]. Thus, the price 
point set by early innovative treatments plays an important 
role, while expenses related to research and development, 
clinical trials, royalties, failed products, and marketing fur-
ther add to the overall price [9, 11].
Parenteral administration
Depending on the disease indication and stage of treat-
ment, patients can require high-dose  mAb administra-
tion as frequent as every 2 weeks for a prolonged period 
of time. The majority of approved mAbs are administered 
by intravenous (i.v.) infusion. Drawbacks of this delivery 
route are the fluctuating mAb pharmacokinetics (peaks 
and troughs), risk of bloodstream infections, hours-
long administration, need for a hospital setting, and 
infusion-related adverse events [12, 13]. Subcutaneous 
(s.c.) injection is rapidly gaining ground as a more prac-
tical alternative. It is generally limited to a few minutes, 
may eventually be suited for self-administration at home, 
and results in less fluctuating mAb pharmacokinetics 
[14]. Because the volume of injection has to be limited 
(1–5  ml) for pain reasons, s.c. formulation may require 
excipients that facilitate administration. In addition, the 
product needs to diffuse in the extracellular matrix to 
reach the blood, resulting in a delay in absorption and 
lower bioavailability compared to i.v. injection. Regarding 
specific side-effects, s.c. delivery can lead to injection-site 
reactions, including erythema and pain, and may be more 
immunogenic than i.v. administration [14]. Irrespective 
of the route of administration, systemic mAb circula-
tion can evoke problems. These include dismal efficacy 
due to difficulties in reaching the target, e.g. penetrating 
solid tumors [15, 16] or crossing the blood–brain barrier 
[17], or specific systemic side-effects, e.g. with immune 
checkpoint inhibitors such as ipilimumab [18, 19], a 
mAb targeted at cytotoxic T-lymphocyte associated pro-
tein 4 (CTLA-4). More local administration routes, e.g. 
the tumor, are pursued, but most are in an early clinical 
phase.
Recap
The issues with regard to the cost and dosing of conven-
tional mAb therapy can restrict (i) access to therapy, (ii) 
implementation of more effective treatment modalities, 
e.g. mAb combinations [3, 8], and (iii) penetration into 
cost-sensitive indications or markets, including infec-
tious diseases and prophylactic use [20]. Overall, these 
hurdles clearly illustrate the need for innovations in mAb 
production and administration.
The case for antibody gene transfer
Concept
In vivo antibody gene transfer seeks to administer to 
patients the mAb-encoding nucleotide sequence, rather 
than the mAb protein. This allows the patient’s body 
to produce the therapeutic mAb of interest for a pro-
longed period of time, and secrete it either systemically 
or locally, depending on the production site (Fig.  1). 
Gene-based antibody therapy presents a labor- and cost-
effective alternative to the conventional production, 
purification and administration of mAb proteins. Three 
antibody expression platforms have been pursued in vivo: 
viral vectors, naked DNA and RNA (Fig.  1a), each of 
which are cheaper to produce than mAb proteins. Anti-
body gene transfer can enable cost-savings by reducing 
the cost of goods and of production, and the frequency of 
drug administration. Overall, a prolonged in vivo produc-
tion of mAbs can contribute to (i) a broader therapeutic 
or prophylactic application of mAbs in price-sensitive 
conditions, (ii) an improved accessibility to therapy in 
both developed and developing countries, and (iii) more 
effective and affordable treatment modalities, e.g. by 
facilitating nucleotide-based mAb cocktails or local mAb 
expression. In addition to in vivo antibody gene transfer, 
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cells can be harvested from the host, engineered to pro-
duce mAbs and re-administered (reviewed in [21, 22]). 
This ex vivo antibody gene transfer is beyond the scope of 
the current review.
Applications
The history of pre-clinical and clinical studies of anti-
body gene transfer spans more than two decades (Fig. 2), 
and reflects the continuous innovations in the applied 
Fig. 1 Principle and versatility of antibody gene transfer. a Schematic overview of the basic principle of antibody gene transfer. Starting from the 
antibody sequence, the encoding nucleotides are placed into viral vectors (adenovirus, adeno-associated virus, or oncolytic virus), naked DNA 
(plasmid or minicircle), or messenger RNA (mRNA), and administered to the host. Following injection, the encoding nucleotides enter the cells 
after which antibody production can commence. b Sites in the body potentially amendable to clinical antibody gene transfer administration or 
production, based on pre-clinical and clinical antibody gene transfer studies with the three different expression platforms. The muscle and liver (via 
intravenous delivery) have been most often reported. Others include the brain [34, 37, 75–78], eye [81], intranasal route [38, 55, 72, 79, 80], trachea 
[56], tumors (either directly injected or via intravenous delivery [30, 36, 39, 99–101, 103, 104, 106–109]), pleura [57, 82, 83], peritoneum [45, 60, 84], 
skin (intradermal [44] and subcutaneous [45]), and spinal canal [40]
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expression platforms. In line with the broad applicability 
of mAbs, antibody gene transfer has been used in a myr-
iad of indications including cancer, infectious diseases, 
inflammatory diseases and central nervous system (CNS) 
diseases (Table 1). In addition to full-length IgG, in vivo 
expressed mAb products include antibody-protein fusion 
products (e.g. immunoadhesins [23, 24]), bispecifics [25–
27] and fragments (e.g. antigen-binding fragment (Fab) 
[28–30], single-chain variable fragment (scFv) [31–41], 
and single-domain antibodies [27, 42–45]). Figure  1b 
depicts the sites on the body potentially amendable to 
antibody gene transfer, based on pre-clinical and clini-
cal studies. Intramuscular antibody gene administration 
has been most widely evaluated (reviewed in [46]), and 
also carries the highest clinical translatability and appli-
cation. Indeed, the inherent anatomical, cellular and 
physiological properties of skeletal muscle make it a sta-
ble environment for long-term mAb expression and sys-
temic circulation [47]. Skeletal muscle is easily accessible, 
allowing multiple or repeated administrations. The abun-
dant blood vascular supply provides an efficient transport 
system for secreted mAbs into the circulation. The syn-
cytial nature of muscle fibers allows dispersal of nucleo-
tides from a limited site of penetration to a large number 
of neighboring nuclei within the fiber. Skeletal muscle 
fibers are also terminally differentiated cells, and nuclei 
within the fibers are post-mitotic [47, 48]. As a conse-
quence, integration in the host genome is not a prereq-
uisite to attain prolonged mAb expression [48]. The liver 
is another site often used for pre-clinical antibody gene 
transfer, and is typically transfected via i.v. injection. This 
organ has various physiological functions, including the 
Fig. 2 Timeline of antibody gene transfer milestones. The first peer-reviewed pre-clinical studies or clinical trials for each of the different expression 
platforms (viral vectors, naked DNA, and mRNA) are ranked in chronological order. AdV adenovirus, rAAV recombinant adeno-associated virus, AGT 
antibody gene transfer, mRNA messenger RNA. Illustrations from top to bottom represent the viral, naked DNA and mRNA expression platforms
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Table 1 Pre-clinical antibody gene transfer studies ranked according to expression platform and indication
AdV adenovirus, CNS central nervous system, rAAV recombinant adeno-associated virus, pDNA plasmid DNA, mcDNA minicircle DNA, HIV human immunodeficiency 
virus, SIV simian immunodeficiency virus, mRNA-LNP messenger RNA encapsulated in lipid nanoparticles
Expression platform Disease indication References
Viral vector
 AdV Cancer [31, 32, 59]
Infectious diseases Clostridium botulinum [45]
Clostridium difficile [43]
Influenza [55]
Respiratory syncytial virus [57]
Yersinia pestis [38, 166]
West Nile virus [167]
Other Pulmonary edema [56]
 rAAV Cancer [71, 83, 84, 168–172]
CNS Alzheimer’s disease [35, 37, 73–78, 173, 174]
Huntington disease [76, 173]
Prion disease [33, 34, 175]
Infectious diseases Anthrax [42, 82]
Ebola [72]
Hepatitis C [176]
HIV (in mouse) [70, 177–179]
SIV (in rhesus macaque) [23, 24, 90–92]
Influenza [55, 79, 80, 180]
Malaria [181]
Respiratory syncytial virus [57]
Other Addiction [182, 183]
Gelsolin amyloidosis [27]
Contraception [184]
Macular degeneration [81]
 Oncolytic virus Cancer [30, 36, 39, 99–101, 103, 104, 106–109]
Naked DNA
 pDNA Auto-immune disease [131]
Cancer [141, 185, 186]
Infectious diseases Chikungunya virus [29]
Dengue virus [136]
Ebola [137, 138, 187]
Hepatitis B [133]
HIV [28]
Influenza [134]
Pneumonia [25]
 mcDNA Cancer [26]
Inflammatory diseases Arthritis [143]
Skin allograft survival [144]
RNA
 mRNA-LNP Cancer [44]
Infectious diseases Clostridium botulinum [44]
HIV [150]
Influenza B [44]
Rabies [44]
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synthesis of plasma proteins. While this makes it poten-
tially well suited for in vivo mAb production, accessibility 
beyond i.v. injection presents a challenge. The tumor pre-
sents another popular site for pre-clinical antibody gene 
transfer, targeted either via i.v. or direct injection in pre-
clinical studies. It carries high clinical relevance, despite 
lacking the accessibility, stability and homogeneity the 
muscle is touted for. Indeed, intratumoral mAb expres-
sion can allow for a local production of the therapeutic, 
waiving the need for high systemic mAb levels often 
required to penetrate and impact solid tumors [15, 16]. 
A similar reasoning applies for the brain, which is fre-
quently targeted in the context of antibody gene transfer 
to avoid the difficulties with blood–brain barrier traffick-
ing [17]. 
Viral vector-mediated antibody gene transfer
Rationale
Viral vectors are currently used as a delivery vehicle in the 
vast majority of pre-clinical and clinical gene therapy tri-
als [49]. The main driver thereto is their exceptional gene 
delivery efficiency, which reflects a natural evolutionary 
development. Vector drawbacks include a complex pro-
duction, a limited packaging capacity for incorporation 
of exogenous DNA, immunogenicity, cytotoxicity, and, 
in some cases, risk of insertional mutagenesis [50, 51]. 
Adenoviruses (AdV) and adeno-associated viruses (AAV) 
are most often applied for gene therapy applications 
[49], including pre-clinical antibody gene transfer. Ret-
roviruses have been used in only a very limited number 
of antibody gene transfer studies [52, 53], which is likely 
related to their inherent risk of insertional mutagenesis. 
These reports are not elaborated on in the current review.
Adenoviral vectors
AdVs are non-enveloped, double-stranded DNA viruses 
that neither integrate in the host genome nor replicate 
during cell division [54]. As early as 1995, Deshane et al. 
[41] reported on the intraperitoneal delivery of an AdV-
based vector to express an anti-human epidermal growth 
factor receptor 2 (HER2) scFv intrabody in mouse can-
cer models. In subsequent years, AdV-mediated antibody 
gene transfer has shown therapeutic efficacy in differ-
ent pre-clinical disease models (Table 1). Systemic mAb 
expression has mostly been pursued, via s.c. [45] and 
especially i.v. and intramuscular AdV injection (reviewed 
in [46]). A series of studies has focused on a more local 
mAb production in mice, either via intranasal [38, 55], 
intratracheal [56] or intrapleural administration [56, 57] 
of the encoding AdV (Fig. 1b). The use of AdVs as onco-
lytic vectors is discussed in a separate section. Overall, 
AdV-mediated mAb expression has shown to be highly 
variable and fairly transient (reviewed in [22]). Peak 
serum concentrations higher than 1  mg/ml have been 
reported a few days after AdV delivery. Within 1  week 
mAb titers typically began to decline, and long-term con-
centrations ranging from 20 ng/ml to 40 µg/ml have been 
reported [58, 59].
Building on their earlier pre-clinical work [41, 60], 
Alvarez et al. initiated in 1998 a Phase I trial to evaluate 
a single intraperitoneal administration of an AdV dose 
coding for an anti-HER2 scFv intrabody [61, 62]. Fifteen 
patients with recurrent ovarian HER2+ cancer were 
included. No dose-limiting vector-related toxicity was 
reported. In ascites, intrabody expression was detected in 
11 of 14 evaluable patients 2 days after AdV administra-
tion and in eight out of 13 evaluable patients on day 56. 
In cell pellets from the ascites, intrabody expression was 
present in ten of 14 evaluable patients at day 2, a num-
ber that decreased to five out of 12 evaluable patients at 
day 14. By day 56, only one out of 11 evaluable patients 
still had detectable intracellular expression. All study 
patients had detectable serum antibodies to AdV prior to 
treatment. Serial serum samples were obtained up to day 
56 in six patients. All but one of the six patients had an 
increase in anti-AdV antibody titers [62]. No follow-up 
clinical studies of this particular trial have been reported. 
In line with the study findings, many AdVs are indeed 
highly prevalent in the general population [63], and pre-
existing immunity can limit the clinical efficacy of AdV-
mediated gene transfer. Of note, the first gene therapy 
death in 1999 was a direct consequence of inflammatory 
immune responses and toxicity against an AdV [64], illus-
trating the safety issues linked to vector immunogenicity. 
Overall, the prevalence of pre-existing anti-AdV immu-
nity coupled with the transient nature of the resulting 
mAb expression has limited enthusiasm for AdVs [22].
Adeno‑associated viral vectors
AAVs are non-enveloped small, single-stranded DNA 
viruses capable of infecting both dividing and non-divid-
ing cells. Similar to AdV, AAV-based vectors remain in an 
episomal state in the nucleus and display a limited risk of 
integration [65, 66]. In contrast to the limited durability 
of AdV-mediated gene transfer, transgene expression can 
persist for years following intramuscular recombinant 
AAV (rAAV) vector delivery [67].
Alipogene tiparvovec (Glybera™), an rAAV encoding 
the human lipoprotein lipase gene, was approved in 2012 
as the first gene therapy product in Europe [68]. Market 
authorization, however, did not translate into commer-
cial success. The product received intense scrutiny for 
its $1  M price tag [69] and failed to penetrate its niche 
market. In April 2017, the company announced that it 
will not pursue renewal of the marketing authorization in 
Europe when it is scheduled to expire in October 2017. 
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This decision was not related to any efficacy or safety 
issue, but merely driven by its very limited use. Indeed, 
various rAAV-based gene therapy products are currently 
under clinical evaluation.
In the context of antibody gene transfer, Lewis et  al. 
[70] in 2002 were the first to demonstrate in  vivo pro-
duction of an anti-human immune deficiency virus 
(HIV) mAb in mice following intramuscular injection 
of the mAb-encoding rAAV. Although relatively low-
level mAb production was observed in vivo (<10 µg/ml), 
expression persisted for at least 6  months, and a clear 
dose–response was observed between the amounts of 
administered vector and resulting mAb titers [70]. Fur-
ther improvements in expression cassette design have 
led to peak serum mAb levels in the single-digit mg/ml 
level in mice, with sustained production up to 1  mg/ml 
for months following rAAV delivery [71]. Similar results 
have been reported since (reviewed in [22, 46]), and 
rAAV-mediated antibody gene transfer has shown effi-
cacy in a myriad of pre-clinical disease models (Table 1). 
Its potential for combination therapy has also been dem-
onstrated, i.e. by expressing two mAb components of the 
anti-Ebola ZMapp™ [72]. Similar to AdV, intramuscular 
and i.v. rAAV administration have been most often pur-
sued (reviewed in [46]). A variety of additional delivery 
sites have been probed to achieve a more local therapeu-
tic effect. These include the intracranial [34, 37, 73–78], 
intranasal [72, 79, 80], intravitreal [81], intrathecal [40], 
intrapleural [82, 83], and intraperitoneal route [84] 
(Fig. 1b).
rAAV-mediated antibody gene transfer has made most 
progress in the field of human immunodeficiency virus 
(HIV) (reviewed in [46, 85–88]), a relevant disease indi-
cation. Indeed, current HIV vaccines fail to generate 
neutralizing antibodies that prevent HIV infection and 
acquired immune deficiency syndrome (AIDS). The last 
5–10 years has seen an accumulation of potent, broadly-
neutralizing mAbs (bnAbs) against HIV [89]. However, 
the cost and frequent infusion associated with conven-
tional mAb administration hampers their therapeutic or 
prophylactic application, paving the way for alternatives 
such as antibody gene transfer. Several antibody gene 
transfer studies in rhesus monkeys, weighing 2–17  kg, 
against simian immunodeficiency virus (SIV) have been 
conducted [23, 24, 90–92]. In an initial study by Johnson 
et al. [23] in 2009, rhesus macaques received intramuscu-
lar injection of rAAVs coding for various anti-SIV immu-
noadhesins (antibody-protein fusion molecules). Six of 
the nine monkeys receiving rAAV-based immunoad-
hesins were protected after SIV challenge, while all six 
naïve controls became infected. The three monkeys from 
the rAAV-immunoadhesin group that became infected 
had developed a humoral antibody immune response 
to the immunoadhesins, leading to undetectable immu-
noadhesin levels 4  weeks after administration, the time 
of SIV challenge. In the protected animals, immunoad-
hesin titers ranged between 3 and 190 µg/ml at the time 
of SIV challenge, depending on the type of rAAV used. 
Immunoadhesin titers peaked around 6  months after 
rAAV injection, reaching 400  μg/ml in some animals 
[23]. Longitudinal studies of the protected monkeys, 
more than 6  years post-injection, showed that immu-
noadhesin levels dropped after 2  years to a stable level 
of approximately 20 μg/ml, which was maintained for at 
least 4 years [93]. A subsequent study converted some of 
these immunoadhesins into authentic IgG, resulting in 
anti-SIV mAbs that contained only rhesus IgG sequences 
[94]. rAAV-mediated delivery, however, was unable to 
obviate a humoral response against the expressed mAbs 
[91]. In a follow-up study, the magnitude of the anti-anti-
body responses was shown to correlate with the sequence 
divergence of the delivered mAb from the germline, 
even in fully rhesus mAbs [92]. Saunders et al. [90] also 
experienced the restrictive nature of antibody-mediated 
immunity when expressing a “rhesusized” mAb. Only 
when the host immune system was suppressed with 
cyclosporine A, the rAAV-expressed rhesusized mAb 
could circulate in macaques for 16 weeks at serum levels 
up to 66 μg/ml [90]. Finally, Gardner et al. [24] injected 
rhesus macaques intramuscularly with an rAAV encod-
ing the anti-HIV rhesus eCD4-Ig, a fusion protein based 
on the immunoadhesin CD4-Ig. As a result, 17–77  μg/
ml of eCD4-Ig was expressed for more than 40 weeks in 
circulation, and macaques were protected from several 
SIV challenges. Two of four monkeys had a weak anti-
eCD4-Ig response, the other two showed none. Of note, 
rAAV-expressed rhesus forms of bnAbs elicited higher 
anti-antibody responses compared to the rhesus eCD4-Ig 
[24]. This could relate to the extensive sequence identity 
with germline sequences and the minimal non-germline 
sequences of eCD4-Ig [92]. In 2013, the International 
AIDS Vaccine Initiative initiated the first Phase I clinical 
trial of rAAV-mediated antibody gene transfer to evalu-
ate safety and tolerability of intramuscular injection of 
rAAV-encoding PG9, an HIV-bnAb [95]. As of May 
2017, no interim results have been reported, and recruit-
ment reportedly is still ongoing (ClinicalTrials.gov: 
NCT01937455). With robust data in rhesus macaques 
and an ongoing clinical trial, rAAV is currently the plat-
form of choice for intramuscular viral-vectored antibody 
gene transfer.
Oncolytic viruses
Oncolytic viruses promote anti-tumor responses through 
selective tumor cell killing and induction of systemic 
anti-tumor immunity [96]. The mechanisms of action are 
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not fully elucidated but are likely to depend on viral rep-
lication within transformed cells, induction of primary 
cell death, interaction with tumor cell anti-viral elements 
and initiation of innate and adaptive anti-tumor immu-
nity [96]. Many of the oncolytic viruses that are currently 
in the clinic have a natural tropism for cell surface pro-
teins that are aberrantly expressed by cancer cells. To 
date, AdV, poxviruses, coxsackieviruses, poliovirus, mea-
sles virus, Newcastle disease virus, reovirus, and others 
have entered into early‐phase clinical trials [96]. In 2015, 
the FDA and EMA approved talimogene laherparepvec 
(T-VEC, Imlygic™), an oncolytic herpes virus armed 
with the gene for granulocyte–macrophage colony-stim-
ulating factor (GM-CSF) [96, 97]. The self-perpetuating 
nature of oncolytic viruses makes them an appealing 
platform for antibody gene transfer, as transgene prod-
ucts can be amplified along with viral replication, thereby 
maximizing therapeutic effect [98].
The first category of mAbs used to arm oncolytic viruses 
were the tumor-targeting mAbs. Local intratumoral 
expression presents an appealing strategy to overcome 
poor mAb penetration in solid tumors [15, 16]. In a first, 
Frentzen et al. [36] in 2009 armed replication-competent 
oncolytic vaccinia viruses with a scFv directed against 
both human and murine vascular endothelial growth 
factor (VEGF). Following i.v. injection, tumor-specific 
delivery and continued scFv production was obtained in 
mouse human lung cancer xenograft models. Serum scFv 
levels were detected up to 37  days after virus injection, 
with peak levels of 1.4 µg/ml. Corresponding scFv levels in 
tumor fluid were 12–15 times higher. The anti-VEGF-scFv 
armed virus had a better anti-tumor response than the 
unarmed virus. The enhanced efficacy was comparable to 
treatment of tumors with a one-time i.v. injection of the 
unarmed vector and concomitant multiple intraperitoneal 
injections of the anti-VEGF bevacizumab [36]. Building 
on these results, the same group applied this principle in 
several mouse human cancer models [39, 99, 100] and in 
mouse canine xenograft models [101, 102], paving the way 
towards veterinary medicine. Combination therapy was 
also pursued. Following i.v. administration, armed vac-
cinia viruses induced a constitutive intratumoral expres-
sion of scFvs against VEGF, epidermal growth factor 
receptor, and fibroblast activation protein [103]. Another 
group recently reported similar findings following intra-
tumoral injection of an oncolytic AdV armed with full-
length anti-HER2 trastuzumab [104].
Immunomodulatory mAbs present another, poten-
tially more relevant category to arm oncolytic viruses. 
Indeed, for oncolytic virus therapy, it is desirable to over-
ride immune checkpoint inhibitor networks and thereby 
create a pro-inflammatory environment within the can-
cer. Numerous Phase I trials are currently underway to 
evaluate the combination of oncolytic viruses and conven-
tional immunomodulatory mAb administration [96, 105]. 
However, systemic treatment with checkpoint-blocking 
mAbs can lead to severe immune-related adverse effects 
[18, 19], highlighting the opportunity for local therapies, 
e.g. via mAb-armed oncolytic viruses. Different stud-
ies have pursued this approach in mouse cancer models. 
Dias et  al. [106] in 2012 armed a replication-deficient 
and -competent oncolytic AdV with an anti-human 
CTLA-4 mAb. Following intratumoral delivery in nude 
mice xenograft models, the armed replication-competent 
virus demonstrated an improved anti-tumor effect com-
pared to the unarmed virus, despite the lack of immu-
nological function the anti-human CTLA-4 mAb had in 
these mice [106]. A week after intratumoral injection of 
the armed replication-competent oncolytic virus, mAb 
levels in tumors and plasma were 17 and 0.4  mg/ml, 
respectively. Levels were significantly higher compared 
to those obtained with the replication-deficient armed 
virus, but no significant difference in tumor response 
was observed [106]. In another study, i.v. injection of 
a replicating AdV expressing an anti-murine CTLA-4 
mAb delayed tumor growth in syngeneic mouse models, 
and led to complete regressions when combined with a 
virus encoding GM-CSF. Data on mAb expression was 
not reported [107]. Similar results were obtained with 
daily intratumoral injections for a period of 4–5  days of 
an attenuated measles virus encoding scFv-Fc fusion pro-
teins against CTLA-4 or programmed cell death-ligand 1 
(PD-L1) [108]. Another recent pre-clinical study armed 
oncolytic vaccinia viruses with anti-murine programmed 
cell death protein 1 (PD-1) Fab, scFv or full-length mAb 
[30]. Reflecting virus replication, mAb levels in the tumor 
peaked 3–5 days after intratumoral injection at 9 or 30 µg/
ml, depending on the tumor model. Serum mAb levels 
followed the same trend, albeit threefold or more lower, 
although mAb detection was lost after 5 days. Intratumor-
ally expressed mAbs lasted longer compared to intratu-
moral injection of anti-PD-1 mAb protein, with follow-up 
limited to 11  days after injection. Fab and scFv expres-
sion were not reported. Anti-tumor responses of the 
virus armed with either the anti-PD-1 scFv or mAb were 
superior to the unarmed virus and as effective as the com-
bination of the unarmed virus and systemic anti-PD-1 
mAb protein injections [30]. Most recently, intratumoral 
administration of a combination of an oncolytic AdV and 
a helper-dependent AdV, armed with an anti-PD-L1 mini-
antibody (a scFv CH2-CH3 fusion protein), improved the 
anti-tumor effect of chimeric antigen receptor (CAR) T 
cell therapy in mice [109]. The benefits of locally produced 
anti-PD-L1 mini-antibody could not be achieved by anti-
PD-L1 IgG infusion plus CAR T-cells and co-administra-
tion of an unarmed AdV [109].
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Overall, these results illustrate the therapeutic poten-
tial of mAb-armed oncolytic viruses, although some 
questions remain. None of the above studies evaluated 
the occurrence of a humoral or cell-mediated response 
against the expressed mAb or viral vector, factors that 
can impact prolonged transgene expression in immune 
competent animals. Furthermore, while replication 
competence can boost mAb expression, it also carries 
biosafety concerns.
Recap
Pioneered by AdV, the field of viral vector-mediated anti-
body gene transfer made significant strides in the past 
decades. The myriad of successfully evaluated adminis-
tration routes, pre-clinical models and disease indica-
tions put the capabilities of antibody gene transfer at full 
display. rAAV and muscle emerged as respectively the 
vector and administration site of choice for prolonged 
mAb expression. In the context of vectored intratu-
moral antibody gene transfer, oncolytic viruses have a 
distinct advantage, as they can specifically target tumor 
cells, boost mAb expression, and amplify therapeutic 
responses. Moving forward, vector-mediated delivery 
still faces several issues that may limit its broad clinical 
use, with the various flavors of immunogenicity being the 
most critical [51, 63, 87]. First, a significant portion of 
the population has already been exposed to the applied 
viruses and thus harbors pre-existing immunity [22, 
110]. The presence of pre-existing or induced antibody-
based immunity against the viral vector can significantly 
decrease the efficacy of vectored expression strategies, 
and also limit the utility of the same serotype of a vec-
tor for repeated administration [87]. Second, cell-medi-
ated response against the vector particle or transgene 
product can eliminate the transduced cells, whereas the 
innate response can cause local and/or systemic toxicity 
and enhance a secondary antigen-dependent immune 
response [111]. Third, for oncolytic viruses specifically, 
a functional adaptive immune system can restrain viral 
multiplication [96], providing a source of uncertainty in 
a clinical setting. Fourth, a humoral antibody response 
against the expressed mAb can lead to a rapid loss of 
mAb detection, as illustrated repeatedly in the rAAV 
non-human primate (NHP) studies. In response, various 
strategies are currently under development to evade or 
prevent these different immune responses [88, 112, 113].
DNA-mediated antibody gene transfer
Rationale
In 1990, Wolff et al. [114] showed how injection of naked 
plasmid DNA (pDNA) into the skeletal muscle of mice 
led to the local expression of the encoded protein, kick-
starting the field of DNA-based therapeutics. pDNA 
waives the need for a virus as biological vector, and pre-
sents an appealing platform for antibody gene transfer. 
Compared to viral vectors, pDNA is considered low-
immunogenic (allowing e.g. repeated dosing), is cheaper 
to produce, ship, and store, and has a much longer shelf-
life. After entry in the nucleus, pDNA remains in a non-
replicating non-integrating episomal state, and is lost 
during the breakdown of the nuclear envelope at mitosis. 
pDNA has no defined restrictions regarding the size of 
the transgene compared to viral vectors, and its modu-
lar nature allows for straightforward molecular cloning, 
making them easy to manipulate and design for thera-
peutic use [115]. Plasmids are used in about 17% of the 
ongoing or completed gene therapy clinical trials [49], 
and showed to be well-tolerated and safe [116]. A plas-
mid-based pharmaceutical for humans has not been mar-
keted, although several clinical trials entered Phase II–III 
[49]. The main disadvantage of pDNA compared to viral 
vectors is the lower transgene expression, which the field 
continues to address by innovating DNA administration 
and construct design.
DNA administration
The method of DNA administration can greatly improve 
transgene expression. In  vivo DNA-mediated antibody 
gene transfer has been exclusively reported with physical 
methods of transfection, i.e., electroporation or hydro-
dynamic injection. Electroporation presents the propa-
gation of electrical fields within tissues, which induces a 
transient increase in cell membrane permeability [117]. 
Electrotransfer of DNA is a multistep process, involv-
ing (i) electrophoretic migration of DNA towards the 
plasma membrane, (ii) DNA accumulation and interac-
tion with the plasma membrane, and (iii) intracellular 
trafficking of the DNA to the nucleus, after which gene 
expression can commence [117]. The first gene electro-
transfer clinical trial was initiated in 2004 [118]. By 2015, 
over 50 trials had used electrotransfer for direct gene 
delivery in vivo or ex vivo [117]. Therapeutic gene elec-
trotransfer approaches include DNA vaccines, immuno-
therapeutic agents, cell-growth inhibitors, pro-apoptotic 
agents, tumor antigens, and anti-angiogenic agents. 
Intramuscular, intratumoral and intradermal administra-
tion have been evaluated in clinical trials [117, 119]. In 
human subjects, application of electric pulses reportedly 
led to short-term pain or discomfort [120]. This transient 
pain can vary depending on the electrical parameters, 
the electrode used, and site of pulse delivery. It may be 
diminished or ultimately eliminated, e.g. by decreasing 
the applied voltage or by varying pulse frequency [119]. 
To support consistent procedure application independ-
ent of operator skill or experience, a great deal of efforts 
has focused on the integration of DNA administration 
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and electroporation application into a single automated 
device [119].
Hydrodynamic-based transfection implies the i.v. 
injection of high volumes of pDNA, driving DNA mol-
ecules out of the blood circulation and into tissue. In 
mice models, hydrodynamic tail injection (HTI) is typi-
cally used for liver transfection. This technique might 
be amenable to use in humans but would be limited 
to locations at which a temporary increase in pressure 
could be created, e.g. by using a blood-pressure cuff 
applied to a limb [121]. Other potentially less invasive 
physical delivery methods include sonoporation and 
magnetofection, but these currently lack application 
for antibody gene transfer and clinical evaluation [122]. 
DNA uptake can also be improved by complexing the 
molecules with chemical delivery vehicles (e.g. cationic 
lipids or polymers and lipid nanoparticles) [123]. While 
these methods are less invasive than physical methods, 
they are in the early phases of clinical development. 
None have been applied for in vivo DNA-mediated anti-
body gene transfer.
DNA backbone
In addition to the choice of delivery method, transgene 
expression can be improved by modifying the make-up 
of pDNA constructs [115, 124]. Conventional pDNA 
consists of a transcription unit and bacterial backbone. 
The transcription unit carries the encoding sequence 
along with regulatory elements. The bacterial backbone 
includes elements like an antibiotic resistance gene, an 
origin of replication, unmethylated CpG motifs, and 
potentially cryptic expression signals. Some of these 
sequences are required for the production of plasmid 
DNA, but each of them can carry biological safety risks 
(reviewed in [125]). Moreover, the unmethylated bacte-
rial CpG motifs can be immunostimulatory, resulting in 
silencing the expression of the encoded transgene [126–
128]. For therapeutic gene therapy, including antibody 
gene transfer, the presence of a bacterial backbone is 
clearly counterproductive. Of the different types of avail-
able minimal vectors [124], so far only minicircle DNA 
(mcDNA) has been reported for antibody gene transfer. 
Minicircles are plasmid molecules devoid of bacterial 
sequences, generated via a process of recombination, 
restriction and/or purification [124]. Elimination of the 
bacterial backbone has shown higher transfection effi-
ciency and prolonged transgene expression in a variety 
of tissues [124, 128–130]. Despite the benefits of these 
minimal vectors, clinical introduction is lagging behind 
because of the challenging manufacturing. Ongoing 
advances in production and purification are expected to 
overcome these technical hurdles and promote clinical 
introduction [124].
Plasmid DNA
The first reports in mice on the use of pDNA for intra-
muscular antibody gene electrotransfer date back from 
2004 [131, 132]. Modest serum mAb titers were attained, 
ranging from a few hundred nanogram to a single micro-
gram per ml [131, 132]. Since then, proof of concept has 
been demonstrated in different mouse disease models, 
mainly in infectious diseases (Table 1). Despite renewed 
interest in recent years, the use of pDNA still lags behind 
that of viral vectors. This is in part related to the signifi-
cantly lower mAb titers associated with DNA-based gene 
transfer. To expand its application, different approaches 
have pursued a higher mAb expression or overall efficacy 
in mice. A first strategy simply relies on giving multiple 
or repeated pDNA doses [133, 134]. Electrotransfer of 
30  µg pDNA in three muscles each instead of one, e.g., 
led to mAb serum titers up to 20 µg/ml [134]. A second 
approach relates to the use of a delivery adjuvant. pDNA 
electrotransfer can be enhanced by pre-treating the mus-
cle with hyaluronidase, an enzyme that transiently breaks 
down hyaluronic acid, decreasing the viscosity of the 
extracellular matrix and facilitating DNA diffusion [135]. 
For antibody gene transfer, this led to an increase in mAb 
expression by approximately 3.5-fold, achieving plasma 
peak titers of 3.5 µg/ml with 30 µg pDNA [134]. A third 
strategy focuses on antibody or cassette engineering. Fol-
lowing codon-, RNA- and leader sequence-optimization, 
peak serum mAb or Fab titers of 1–3  µg/ml have been 
attained with intramuscular electrotransfer of 25–100 µg 
‘optimized’ pDNA [28, 29, 136]. However, expression 
titers from the ‘non-optimized’ pDNA went largely 
unreported, making it difficult to appreciate the impact 
of these modifications. Recently presented data showed 
how framework grafting and/or scFv-Fc conversion could 
increase serum levels of some poorly expressed mAbs up 
to a tenfold, resulting in peak titers of 6 µg/ml [137]. For 
mAbs that already showed high expression in an unmodi-
fied state, this engineering increased serum peak levels 
by about a threefold. Intramuscular electrotransfer of 
200 µg pDNA thereby resulted in titers of approximately 
20–30 µg/ml of the grafted scFv-Fc [138]. A fourth strat-
egy is dedicated to improving efficacy via rational com-
bination approaches. Simultaneous expression of up to 
three mAbs against multiple dengue virus serotypes, e.g., 
increased the breadth of viral coverage in mice [136]. 
Similarly, combining a DNA-based mAb with DNA-
based antigen vaccination improved protection against 
the Chikungunya virus in mice [29].
Naked pDNA is not considered as immunogenic as 
viral vectors. The low immunogenicity of pDNA, how-
ever, does not exclude a humoral response against the 
expressed mAb. Indeed, serum mAb titers in mice have 
shown to decline in  vivo 7–14  days after intramuscular 
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pDNA electrotransfer due to the development of an 
antibody response against the expressed human mAb 
[132]. In contrast, the pDNA-mediated production of a 
fully murine mAb persisted in the circulation for over 
7 months [132]. Similar findings were observed in subse-
quent studies, where mAb-encoding pDNA electrotrans-
fer in immune compromised mice showed no decrease in 
mAb levels after a month [133].
The above studies consistently used intramuscular 
electrotransfer to induce mAb expression. One notable 
exception is the study by Kitaguchi et  al. [133] in 2005, 
in which HTI and electrotransfer were evaluated side by 
side. HTI of a 40  µg pDNA dose led to single-digit µg/
ml mAb peak titers in plasma 3 days after injection. mAb 
levels, however, rapidly decreased and detection was vir-
tually gone after 100  days. Intramuscular electrotrans-
fer of an identical pDNA dose led to tenfold lower peak 
mAb levels at day 7, with little decrease towards the end 
of the 100 day follow-up [133]. Despite the higher mAb 
peak titers, HTI has not been further pursued for pDNA-
based antibody gene transfer, possibly because of its dif-
ficult translation to the clinic.
Limited data is available for pDNA-mediated antibody 
gene transfer other than in mice. Tjelle et  al. [132] in 
2004 injected sheep, weighing 15–17 kg, intramuscularly 
with 100  μg of pDNA-encoding murine mAb, followed 
by electroporation. Six of seven sheep had detectable 
serum mAb levels at 30–50  ng/ml, up to 2  weeks after 
pDNA administration. An abrupt decline in mAb levels 
2  weeks after pDNA administration was linked to anti-
body responses raised against the foreign mouse mAb. 
Considering these results were obtained with a dose 
similar to that delivered in mice and using a non-optimal 
mAb sequence, there clearly remained room for improve-
ment [132]. Recently presented data showed transient 
low-single-digit µg/ml serum levels of human mAbs in 
rabbits and NHP, following hyaluronidase pre-treatment 
and intramuscular electrotransfer of several milligrams 
of mAb-encoding pDNA [139]. Albeit promising, these 
mAb titers remain a far cry from those attained with 
viral vectors in NHP. Moreover, these animal models are 
still significantly smaller than a human adult, leaving the 
question of translatability unanswered.
In 2010, a first Phase I–II of DNA-based antibody ther-
apy was initiated by Scancell Ltd (UK) (ClinicalTrials.gov: 
NCT01138410). In patients with stage 3–4 melanoma, a 
pDNA that encodes SCIB1, a mAb engineered to stimu-
late a T-cell response against melanoma, was adminis-
tered intramuscularly followed by electroporation [140, 
141]. Outcome measures included safety, tolerability, 
and biological and clinical effects. During a time period 
of 5.5 months, patients received five intramuscular doses 
of the SCIB1-encoding pDNA. The first part of the trial 
was a dose-escalation study (0.4, 2, 4, and 8  mg). The 
Clinical Study Report, released in January 2017 by the 
company, stated that SCIB1 was safe and well tolerated. 
mAb expression led to dose-dependent immunological 
responses and proof of clinical activity in some of the 
patients, with 8  mg identified as the preferential pDNA 
dose. mAb pharmacokinetics were not reported [142].
Minicircle DNA
mcDNA-based antibody gene transfer is fairly recent and 
so far limited to studies in mice. In contrast to pDNA, 
mcDNA has been exclusively administered   via HTI. Yi 
et al. in 2014 were the first to evaluate mcDNA for anti-
body gene transfer, focusing on two marketed mAbs in the 
field of inflammatory diseases: tocilizumab, a mAb against 
interleukin 6 receptor, and etanercept, an Fc fusion pro-
tein against soluble TNF [143]. Fifteen days after HTI 
of 16  μg of mcDNA, tocilizumab peaked at 40–60  ng/
ml, and dropped below 20  ng/ml 30  days after mcDNA 
administration. Etanercept was detected at 0.3  ng/ml 
5 days after mcDNA HTI, but decreased shortly after and 
was no longer detected 15  days after injection. Despite 
the low mAb titers, a slowing incidence and improve-
ment in arthritis symptoms were observed in mice [143]. 
Building on these results, the same research group con-
structed a fusion construct of tocilizumab and etanercept 
[144]. Five days following HTI of 20  μg of mcDNA that 
encoded tocilizumab, etanercept or the novel fusion con-
struct, serum levels of the corresponding proteins peaked 
at 0.2–0.4 ng/ml and were detectable for at least 10 days 
after mcDNA administration. Albeit extremely low, these 
titers were reportedly sufficient to improve skin allo-
graft survival [144]. In a subsequent pre-clinical study, a 
similar mcDNA-encoded fusion protein was successfully 
evaluated for arthritis [145]. In another study by the same 
group, abatacept, a CTLA4-Fc fusion protein approved 
for autoimmune diseases, was encoded in pDNA and 
mcDNA [146]. HTI of the abatacept-encoding mcDNA 
resulted in a better therapeutic response compared to 
pDNA in arthritis mouse models. However, it was unclear 
whether equimolar pDNA and mcDNA amounts were 
compared. Moreover, neither the concentration nor dura-
tion of the resulting abatacept expression were reported 
[146]. In these initial mcDNA studies [143–146], the 
attained serum mAb levels were up to 10,000-fold lower 
than reported previously for antibody-encoding pDNA 
HTI, despite using comparable equimolar DNA amounts 
[133]. The authors did not elaborate on these substantial 
differences. Plasma mAb titers were also lost considerably 
faster with mcDNA (e.g. after 15 days [143]) compared to 
pDNA HTI (detection for up to 100 days [133]). Although 
not assessed in these mcDNA studies, a humoral anti-
body response likely played a role, as all expressed mAb 
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products contained human sequences. In addition to 
inflammatory diseases, mcDNA has been used to express 
a bispecific anti-CD3/CD20 mAb for the treatment of 
human B-cell lymphomas in a mouse cancer model [26]. 
Following HTI of only 5  µg of the encoding mcDNA in 
immune compromised mice, mAb serum levels peaked 
around 7 µg/ml 24 h later, and dropped sharply to 1.2 µg/
ml on day 3 and to 100 ng/ml after a week. These titers 
were sufficient to induce an anti-lymphoma response [26] 
and were similar to those attained previously with higher 
doses of pDNA, albeit decreasing more rapidly over time 
[133]. Available mcDNA studies show mixed results in 
terms of expressed mAb titers. Indeed, the added value 
of mcDNA over pDNA in the context of antibody gene 
transfer remains subject to further research, given the lack 
of conclusive head-to-head comparisons.
Recap
Compared to viral vectors, pDNA- or mcDNA-based 
gene transfer results in substantially lower mAb titers. 
Therapeutic responses in various mice models have been 
demonstrated (Table  1), but the lack of robust data in 
larger animal models currently casts doubt on its scal-
ability and translatability to the clinic. Moving the needle 
on expressed mAb titers therefore remains a top priority 
for DNA-based antibody therapy. Various innovations, 
e.g. in construct engineering, show clear promise, while 
others, including the use of mcDNA, warrant additional 
evaluation. In terms of delivery, antibody-encoding DNA 
administration so far has been limited to i.v. (liver) and 
muscle (Fig.  1b). Improvements in both physical and 
non-physical DNA transfection methods are required 
to make more administration sites amendable to DNA-
mediated antibody gene transfer, allowing for a broader 
application range.
RNA-mediated antibody gene transfer
Rationale
In their 1990 study, Wolff et al. [114] found that, in addi-
tion to pDNA, intramuscular injection of in  vitro tran-
scribed (IVT) mRNA also led to local expression of the 
encoded protein. mRNA was not pursued as actively as 
DNA at that time because of its low stability. Progress 
over the past years allowed mRNA to catch up with DNA 
and viral vectors as a tool for gene transfer (reviewed in 
[147]). Conceptually, there are several differences with 
these expression platforms. mRNA does not need to 
enter into the nucleus to be functional. Once it reaches 
the cytoplasm, mRNA is translated instantly. mRNA-
based therapeutics are expressed more transiently com-
pared to DNA- or viral vector-mediated gene transfer, 
and do not pose the risk of insertional mutagenesis in the 
host genome. mRNA production is relatively simple and 
inexpensive. In terms of administration, mRNA uptake 
can be enhanced using electroporation [148]. Most focus, 
however, has gone to non-physical transfection meth-
ods. Indeed, a variety of mRNA complexing formula-
tions have been developed, including lipid nanoparticles 
(LNP), which have proven to be safe and very efficient 
mRNA carriers for administration in a variety of tissues 
and i.v. [149]. In line with this progress, IVT mRNA has 
reached the stage of clinical evaluation [147].
Emerging data
Pardi et  al. [150] in 2017 reported the first RNA-based 
antibody gene transfer study in mice using a human 
anti-HIV-1  mAb as model. Twenty-four hours after i.v. 
injection of 30  μg (1.4  mg/kg) of the encoding mRNA 
encapsulated in lipid nanoparticles (mRNA-LNP) in 
BALB/c mice, mAb plasma levels peaked at ~170 μg/
ml and remained between 130 and 170 μg/ml for 5 days. 
mAb concentrations showed a sharp drop by day seven 
and were below detection 11  days post injection. In 
immune compromised mice, weekly i.v. injections of 
30 μg (1 mg/kg) mRNA-LNP were required to maintain 
mAb levels above 40 μg/ml. No comparative data on the 
pharmacokinetics of the mAb administered as protein 
was included. In  vivo produced mAb titers were suffi-
cient to protect the mice from an HIV-1 challenge [150]. 
Already in 2008, CureVac AG (Germany) filed a patent for 
mRNA-based antibody gene transfer (Patent Coopera-
tion Treaty PCT/EP2008/000081). No data was disclosed 
at that time. Recently presented mice data from CureVac, 
however, demonstrate how a single i.v. administration of 
mAb-encoding mRNA-LNP led to dose-dependent mAb 
titers, reaching low single-digit µg/ml range within 2  h 
after mRNA injection [44]. At the highest dose of 40 µg 
of mRNA-LNP, mAb expression peaked in the 10  µg/
ml range after a few days. While expression lasted for 
at least a month, a decrease of a factor 10 or more was 
observed over that period of time. Of interest, this pro-
longed expression was also evident in immune compe-
tent mice for some of the expressed human mAbs [44]. 
mRNA-based expression of single-domain antibodies has 
also been pursued. To increase titers, serum persistence 
was extended via complementing single-domain antibod-
ies with an albumin-binding peptide [44]. i.v. administra-
tion of the encoding mRNA-LNP resulted in peak levels 
of up to 300 µg/ml. Both i.v. and intradermal injection of 
mRNA-LNP encoded mAbs or single-domain antibod-
ies resulted in therapeutic responses in mice models of 
infectious diseases and cancer [44] (Table 1).
Recap
mRNA presents an emerging platform for antibody 
gene transfer. While the first peer-review study with 
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mRNA-based antibodies was only recently published, 
this application has matured behind corporate walls 
for a decade or more. In addition to CureVac, Moderna 
Therapeutics (US) is another RNA company that is cur-
rently leveraging its platform for antibody gene transfer. 
Although current results differ considerably among the 
few available reports, mRNA may be able to rival with 
viral vectors in terms of generated serum mAb titers. 
Levels were in therapeutically relevant ranges within 
hours after mRNA administration, a marked shift in 
speed compared to DNA. The use of LNP for mRNA 
transfection, rather than the physical methods typi-
cally required for DNA, provide a significant advantage 
towards application range, if translated to the clinic. It 
is currently unclear how long RNA-mediated antibody 
expression can last. As more studies become available in 
the near future, the opportunities and limits of mRNA 
as an expression platform for antibody gene transfer will 
become evident.
Remaining challenges and future directions
A broad clinical introduction of antibody gene trans-
fer remains littered with challenges. First, it is unclear 
whether therapeutic mAb titers can be attained and 
maintained in human subjects. Second, the lack of con-
trol on mAb expression can impact safety. Third, immu-
nogenicity against the vector or expressed mAb can limit 
prolonged expression. Fourth, ongoing innovations in 
conventional mAb therapy directly compete with anti-
body gene transfer, potentially impacting the relevance 
of the latter. For each of these challenges, possible paths 
forward are discussed.
Efficacy and side‑effects
The threshold for therapeutic plasma mAb titers in 
patients varies drastically according to the targeted dis-
ease, ranging from nanogram to tens of microgram per 
milliliter [22]. Despite encouraging data in pre-clinical 
models, it is currently uncertain whether the highlighted 
antibody gene transfer platforms are scalable enough to 
attain and maintain therapeutic mAb levels for a broad 
spectrum of indications in human subjects. Innovations 
in expression cassette, antibody format, and adminis-
tration have moved the needle in each of the applied 
expression platforms [44, 71, 94, 137, 138, 150]. However, 
additional innovations remain warranted, especially in 
the non-viral field, to assure clinical relevance. A more 
local mAb production, e.g. in the tumor or brain, presents 
a more pragmatic way to address the possible inability 
of antibody gene transfer to attain systemic therapeu-
tic levels in patients. The relative unpredictability of the 
expressed mAb titers presents an additional challenge. 
If concentrations remain below the therapeutic window 
for a prolonged period of time, development of resistance 
and inferior clinical outcomes are genuine concerns. In 
contrary, over-dosing may increase mAb-associated side 
effects, a risk that is amplified by the lack of expression 
control. To answer the question of pharmacokinetics, 
studies in more relevant animal models in terms of body 
mass, e.g. swine or sheep, could be pursued in anticipa-
tion of human trials. To address the current unknowns in 
terms of expression, clinical implementation of antibody 
gene transfer will likely go hand in hand with therapeutic 
drug monitoring.
Control of expression
As alluded to in the previous section, a mechanism to 
control the duration and amount of in  vivo antibody 
expression is a prerequisite for safe use of antibody gene 
transfer in many of the envisioned applications. While 
inducible promoters have been evaluated in mice with 
both viral vectored- [151] and pDNA-based antibody 
gene transfer [131], the applied systems are not suited 
for clinical translation [152]. To our knowledge, the only 
regulatable mechanism currently under clinical evalu-
ation is an ecdysone-based gene switch activated by a 
small molecule ligand [153]. However, such an approach 
would require a daily drug regimen, crossing the ease 
of use which antibody gene transfer seeks to achieve. 
A more pragmatic approach to cease expression is to 
directly target the site of antibody gene administration, 
if clearly defined and contained. A transfected muscle 
site could e.g. be physically removed or targeted by cal-
cium electrotransfer [154]. However, these methods are 
not desirable for routine use and would merely serve as 
an emergency-stop. Identifying a non-invasive and effi-
cient method to permanently eliminate or tightly regulate 
antibody gene expression in the host therefore remains a 
priority. In the meantime, clinical introduction of anti-
body gene transfer can opt for indications where mAb 
expression control is considered less critical (e.g. when 
targeting non-self antigens in infectious diseases). For 
applications such as immunotherapy or inflammatory 
diseases, a prolonged non-controllable mAb expression 
presents concerns in terms of efficacy and/or side effects. 
The use of expression platforms (e.g. mRNA) or adminis-
tration sites (e.g. tumor or skin) that may result in a more 
transient mAb expression can present a way forward in 
these indications.
Immunogenicity and antibody characterization
Of the three expression platforms discussed, viral vec-
tors suffer most from immunogenicity [51, 63, 87]. The 
development of strategies to evade pre-existing or de 
novo anti-vector immunity or prevent the induction of 
anti-vector immune responses are thus of high relevance 
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for this field [112, 113]. In contrast, the risk of a humoral 
response against the expressed mAb applies to each of 
the expression platforms. In pre-clinical antibody gene 
transfer studies, the absence of an immune response 
has been a critical factor in achieving prolonged expres-
sion. Most, if not all, approved mAbs exhibit some level 
of immunogenicity when administered as conventional 
proteins [155]. It is currently unclear if a mAb that is 
in vivo expressed is more or less immunogenic than when 
administered as an in vitro produced protein. A risk for 
increased immunogenicity could occur because of the 
differences between natural antibody-producing plasma 
cells and transfected cells, e.g. muscle [87, 156–158], or 
because a small portion of the mAb-encoding sequence 
finds its way into antigen-presenting cells, where 
attempts to express the mAb could set off an immune 
response [159, 160]. The use of tissue-specific promoters 
or vector serotypes may be of value in this context [159]. 
Further work is needed to understand the factors that 
underlie these responses and how to circumvent them. 
Focus thereby should lay on the selection and design 
of low-immunogenic mAbs and expression platforms, 
rather than concomitant immunosuppressive drug regi-
mens. Other related uncertainties are the physicochemi-
cal characteristics of in  vivo expressed mAbs. Product 
variants (glycosylation differences, c-lysine clipped 
forms, etc.) and product-related impurities (truncated 
forms, aggregates, etc.) may vary depending on the pro-
ducing cells, thereby potentially impacting mAb expres-
sion titers, efficacy and immunogenicity [161–163]. To 
elucidate these uncertainties, further study is needed to 
characterize in vivo produced mAbs.
Positioning
Apart from antibody gene transfer, there are multiple 
examples of more conventional innovations that address 
issues with mAb therapy in terms of cost, administra-
tion and efficacy. While mAb production is anticipated 
to remain more expensive than e.g. small molecules or 
antibiotics, advancements in production technologies 
continue to increase yields and reduce manufacturing 
costs [10, 164]. Discomfort and fluctuating pharmacoki-
netics associated with i.v. infusion are being addressed 
by s.c. injection [13]. The need for frequent dosing 
can be overcome by extension of mAb half-life, e.g. 
by introducing point mutations in the mAb Fc region 
[165], mAb PEGylation or sustained-release formula-
tions. The quest for more effective therapies includes 
the development of multispecific mAbs, which presents 
an alternative way to address the need for costly mAb 
combinations. Overall, the field for antibody gene trans-
fer should not remain blind for these innovations, but 
rather take them into account when prioritizing which 
disease indications to go after. Relevant thereby is tar-
geting a real unmet need and therapeutic advantage, 
and to focus on a rapid clinical entry by selecting the 
best suited expression platform. Viral-vectored anti-
body gene transfer in the field of HIV [95], mAb-armed 
oncolytic viruses, and the combination of DNA-based 
vaccines with DNA-based mAbs [29] all present rel-
evant examples thereto.
Conclusions
The state of play of antibody gene transfer is marked by 
substantial progress in the various interacting fields of 
research. While challenges persist, clinical prospects 
are amplified by ongoing innovations and the versatil-
ity of antibody gene transfer. In the near future, clinical 
introduction can be expedited by selecting the platform 
approach currently best suited for a mAb or disease indi-
cation of interest. Innovations in expression platform, 
administration and antibody technology are expected to 
further improve safety and efficacy, and unlock the vast 
clinical potential of antibody gene transfer.
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